<DOC>
	<DOC>NCT01707160</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the pharmacokinetics and pharmacodynamics of insulin X14 30/70 PreMix compared to human insulin 30/70 PreMix in healthy volunteers.</brief_summary>
	<brief_title>Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Nonsmokers BMI (body mass index) maximum 27 kg/m^2 HbA1c (glycosylated haemoglobin A1c): 3.46.1% FBG (fasting blood glucose) maximum 6.0 mmol/L</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>